AFFiRiS raises €10M; FDA clears IND applications for BiondVax flu vax and Genticel HPV jab;

> AFFiRiS raised €10 million in a financing round. The funding will be used to advance its AFFITOME technology for the prevention and therapy of chronic illnesses, including Parkinson's disease. Release

> BiondVax ($BVXV) announced that its Investigational New Drug Application for its universal flu vaccine candidate was accepted by the FDA. News

> Genticel announced that the FDA has cleared its IND to conduct a Phase I study of its HPV candidate. Release

> France-based Biosantech announced that its HIV vaccine candidate is safe and not toxic for patients. The results are based on a study involving 48 HIV-positive patients. More

> The American Medical Association seeks to put an end to exemptions to immunizations that are not for medical reasons. Story

> The Defense Threat Reduction Agency is investing $5.2 million in EpiVax for the development of a new vaccine against Q fever. Release

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.